Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Connect Twitter with Market Wire News

ABEO - Abeona Therapeutics Stock Trading


home / stock / abeo

ABEO ABEO Quote ABEO Short ABEO News ABEO Articles ABEO Message Board

About | Abeona Therapeutics Inc. (NASDAQ:ABEO)

Access Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, two products in Phase development, and five preclinical development programs. The company s approved product is MuGard TM for the management of oral mucositis a common and debilitating side effect of many cancer therapies for which marketing authorization has been allowed by the FDA. Access ProLindac TM , a polymer linked platinum cancer drug is in Phase clinical testing in cancer patients, as is Phenylbutyrate, a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. The Company s preclinical development programs include Angiolix, a humanized monoclonal antibody which acts as an anti angiogenesis factor and is potentially targeted to a number of tumor types, including breast and ovarian Prodrax, a non toxic prodrug which is activated in the hypoxic zones of solid tumors to kill tumor cells Alchemix, a chemotherapeutic agent that combines two modes of action to overcome drug resistance, and oral insulin, which utilizes the company s Cobalamin TM oral drug delivery technology.

Quote | Abeona Therapeutics Inc. (NASDAQ:ABEO)

Last:$4.64
Change Percent: 0.21%
Open:$4.65
Close:$4.64
High:$4.7
Low:$4.32
Volume:408,695
Last Trade Date Time:12/04/2023 03:00:00 am

News | Abeona Therapeutics Inc. (NASDAQ:ABEO)

  • Abeona shares jump after FDA priority review for epidermolysis bullosa drug

    2023-11-27 07:50:10 ET More on Abeona Therapeutics Abeona Therapeutics Inc. (ABEO) Q3 2023 Earnings Call Transcript Abeona Therapeutics GAAP EPS of -$0.48 beats by $0.05 Abeona submits FDA market application for rare skin disorder drug Seeking Alpha’s ...

    • November 27, 2023 07:50:10 am
    • |
    • SeekingAlpha
    • |
      • ABEO Stock
      • ABEO Quote
      • ABEO Short
      • ABEO News
      • ABEO Articles
      • ABEO Message Board
  • Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

    - PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has ac...

    • November 27, 2023 07:30:00 am
    • |
    • GlobeNewswire
    • |
      • ABEO Stock
      • ABEO Quote
      • ABEO Short
      • ABEO News
      • ABEO Articles
      • ABEO Message Board

Message Board Posts | Abeona Therapeutics Inc. (NASDAQ:ABEO)

Subject By Source When
whytestocks: $ABEO News Article - Abeona Therapeutics Announces Update on AAV Ophthalmology Program whytestocks investorshangout 03/14/2023 12:21:07 PM
whytestocks: $ABEO News Article - PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week whytestocks investorshangout 11/21/2022 6:35:49 PM
You gots me CONFUSED, Young Lady!! YES, I Invest-in-America investorshub 10/12/2022 2:34:13 PM
you already posted there silly, so i replied gail investorshub 10/12/2022 2:26:24 PM
O.K., I'll take a look at THAT one Invest-in-America investorshub 10/12/2022 2:24:19 PM
Stock Information

Get ABEO Alerts

News, Short Squeeze, Breakout and More Instantly...

Abeona Therapeutics Inc. Company Name:

ABEO Stock Symbol:

NASDAQ Market:

Abeona Therapeutics Inc. Website:

Abeona Therapeutics Inc. Logo

Ad

Connect Twitter with Market Wire News
RECENT ABEO NEWS
  • ABEO - Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

    - PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has ac...

  • ABEO - Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

    Abeona’s first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority review and acceptance of BLA for pz-cel (prademagene zamikeracel, formerly known as EB-101) in recessive dystrophic epidermolysis bullosa (RDEB) expected by ...

  • ABEO - Expected US Company Earnings on Monday, November 13th, 2023

    INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Coins
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your Twitter Account

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.



Market Wire News App

Sign up for the Market Wire News App now!

The Market Wire news app is set to launch soon, be one of the first to try it out before it's in the store.



Be alerted of any news about your stocks and see what other stocks are trending.

Market Wire News App

Sign up for the Market Wire News App now!

The Market Wire news app is set to launch soon, be one of the first to try it out before it's in the store.



Be alerted of any news about your stocks and see what other stocks are trending.

Get ABEO Alerts

Get ABEO Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| Google News

| X

| Facebook

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2023 Market Wire News